Celldex Up As Breast-Cancer Drug Shows Promise
Celldex Therapeutics (CLDX) stock was up 6% in morning trading Tuesday after the biotech company updated its midstage trial results on its breast-cancer drug late Monday. Results from the phase-two trial, called Emerge, of glembatumumab vedotin in metastatic breast cancer were published in the Journal of Clinical Oncology, which Celldex said supported its current trial, Metric, focusing on patients with over-expression of the glycoprotein NMB.